MX2018002546A - Composiciones que comprenden un compuesto de urolitina. - Google Patents

Composiciones que comprenden un compuesto de urolitina.

Info

Publication number
MX2018002546A
MX2018002546A MX2018002546A MX2018002546A MX2018002546A MX 2018002546 A MX2018002546 A MX 2018002546A MX 2018002546 A MX2018002546 A MX 2018002546A MX 2018002546 A MX2018002546 A MX 2018002546A MX 2018002546 A MX2018002546 A MX 2018002546A
Authority
MX
Mexico
Prior art keywords
compositions
urolitine
compound
provides
urolithin
Prior art date
Application number
MX2018002546A
Other languages
English (en)
Inventor
Blanco-Bose William
Andreux Penelope
Rinsch Christopher
Original Assignee
Amazentis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54326546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018002546(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amazentis Sa filed Critical Amazentis Sa
Publication of MX2018002546A publication Critical patent/MX2018002546A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A23L2/66—Proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Dairy Products (AREA)

Abstract

La invención proporciona composiciones que comprenden una fuente de proteínas y una urolitina. La invención también proporciona usos y métodos asociados con, o que hacen uso de las composiciones, tales como un medicamento, suplemento dietético, alimento funcional o alimento médico y en el tratamiento y/o profilaxis de una afección patológica relacionada con los músculos. La invención también proporciona kits que comprenden urolitina y proteína.
MX2018002546A 2015-08-28 2016-08-26 Composiciones que comprenden un compuesto de urolitina. MX2018002546A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1515391.9A GB201515391D0 (en) 2015-08-28 2015-08-28 Compositions
PCT/EP2016/070257 WO2017036993A1 (en) 2015-08-28 2016-08-26 Compositions comprising an urolithin compound

Publications (1)

Publication Number Publication Date
MX2018002546A true MX2018002546A (es) 2018-06-15

Family

ID=54326546

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002546A MX2018002546A (es) 2015-08-28 2016-08-26 Composiciones que comprenden un compuesto de urolitina.

Country Status (17)

Country Link
US (4) US10442784B2 (es)
EP (2) EP3340803B1 (es)
JP (1) JP7161402B2 (es)
CN (2) CN120131635A (es)
AU (4) AU2016314988A1 (es)
BR (1) BR112018003780B1 (es)
CA (1) CA2996725C (es)
DK (1) DK3340803T3 (es)
ES (1) ES2994610T3 (es)
FI (1) FI3340803T3 (es)
GB (1) GB201515391D0 (es)
HU (1) HUE068243T2 (es)
LT (1) LT3340803T (es)
MX (1) MX2018002546A (es)
PL (1) PL3340803T3 (es)
PT (1) PT3340803T (es)
WO (1) WO2017036993A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3026991T3 (en) * 2010-12-23 2025-06-12 Amazentis Sa Non-therapeutic method of increasing or maintaining mitochondrial function
JP6422163B2 (ja) 2012-06-27 2018-11-14 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515391D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
US20210085624A1 (en) * 2017-12-20 2021-03-25 Societe Des Produits Nestle S.A. Compositions and methods using a combination of autophagy inducer and high protein for induction of autophagy
EP3727586A1 (en) * 2017-12-20 2020-10-28 Société des Produits Nestlé S.A. Compositions and methods using high protein for induction of autophagy
IL276886B2 (en) * 2018-02-27 2024-11-01 Amazentis Sa Urolitin A synthesis process
SG11202011261PA (en) 2018-05-15 2020-12-30 University Of Louisville Research Foundation Inc Urolithin a and derivatives thereof for use in therapy
CN109156692A (zh) * 2018-07-20 2019-01-08 合肥英特美乐生物科技有限公司 一种混合天然产物的泡腾片及其制备方法
CA3188397A1 (en) 2020-09-25 2022-03-31 Anupama Dattatreya Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
EP4284781A1 (en) 2021-01-27 2023-12-06 Vandria SA Urolithin derivatives and methods of use thereof
JP2022185501A (ja) * 2021-06-02 2022-12-14 株式会社ダイセル 閉経後の女性の筋肉の重量を増加させるための組成物
GB202219317D0 (en) * 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
GB202308224D0 (en) * 2023-06-01 2023-07-19 Amazentis Sa Formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739855D1 (de) 1996-03-26 2010-06-02 Lilly Co Eli Benzothiophene und denen enthaltende zusammensetzungen
IN224411B (es) * 2002-08-23 2008-12-05 Dsm Ip Assets Bv
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
CN104016951B (zh) 2010-03-19 2016-07-13 北京强新生物科技有限公司 靶向癌症干细胞的化合物和组合物
TR201816320T4 (tr) 2010-03-22 2018-11-21 Instillo Gmbh Mikro- veya nanopartikül üretimi işlemi.
AU2011244783B2 (en) 2010-04-20 2015-11-12 Cipla Limited Pharmaceutical compositions
AU2011332867A1 (en) 2010-11-24 2013-06-20 Exelixis, Inc. BENZOXAZEPINES AS INHIBITORS OF PI3K/mTOR AND METHODS OF THEIR USE AND MANUFACTURE
ES3026991T3 (en) 2010-12-23 2025-06-12 Amazentis Sa Non-therapeutic method of increasing or maintaining mitochondrial function
JP6422163B2 (ja) 2012-06-27 2018-11-14 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
US10405893B2 (en) 2012-07-12 2019-09-10 DePuy Synthes Products, Inc. Device, kit and method for correction of spinal deformity
AU2013101214A4 (en) * 2012-09-11 2013-10-17 Fonterra Co-Operative Group Limited Dairy product and process
EP2945622B1 (en) * 2013-01-18 2022-11-30 Mans, Jean-Pierre Composition comprising urolithin b and testosterone, leucine and/or creatine for muscle growth
GB201323008D0 (en) * 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
GB201515391D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions

Also Published As

Publication number Publication date
US10442784B2 (en) 2019-10-15
BR112018003780B1 (pt) 2022-05-17
EP3340803A1 (en) 2018-07-04
US20240150310A1 (en) 2024-05-09
CN120131635A (zh) 2025-06-13
US12297182B2 (en) 2025-05-13
EP4424368A2 (en) 2024-09-04
EP3340803B1 (en) 2024-06-26
LT3340803T (lt) 2024-10-25
CA2996725A1 (en) 2017-03-09
ES2994610T3 (en) 2025-01-27
US20190062297A1 (en) 2019-02-28
AU2022291500A1 (en) 2023-02-02
PL3340803T3 (pl) 2024-12-09
DK3340803T3 (da) 2024-09-30
WO2017036993A1 (en) 2017-03-09
US20220073488A1 (en) 2022-03-10
US20200140405A1 (en) 2020-05-07
CN108135220A (zh) 2018-06-08
US11878964B2 (en) 2024-01-23
AU2021201143A1 (en) 2021-03-11
FI3340803T3 (fi) 2024-09-27
US10988453B2 (en) 2021-04-27
JP7161402B2 (ja) 2022-10-26
HUE068243T2 (hu) 2024-12-28
PT3340803T (pt) 2024-09-05
AU2021201143B2 (en) 2024-08-08
AU2016314988A1 (en) 2018-03-29
JP2018532769A (ja) 2018-11-08
AU2024278443A1 (en) 2025-01-09
CA2996725C (en) 2024-01-02
EP4424368A3 (en) 2024-11-20
HK1257501A1 (en) 2019-10-25
BR112018003780A2 (pt) 2018-09-25
GB201515391D0 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
MX2018002543A (es) Composiciones que comprenden compuestos de urolitina.
MX2022012374A (es) Composiciones multi-suplementos.
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
MX2018006240A (es) Composiciones que comprenden cepas bacterianas.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
EA201691607A1 (ru) Микроорганоиды и способы их получения и применения
MX378273B (es) Compuestos activos hacia bromodominios.
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
EP3102220C0 (en) SYNERGIC FOOD SUPPLEMENT COMPOSITIONS FOR THE PREVENTION, TREATMENT OR REGULATION OF INFLAMMATORY DISORDERS
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX370628B (es) Composiciones y metodos para tratar las espinillas.
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX392976B (es) Composiciones que comprenden cepas bacterianas.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2017010526A (es) Mezclas de aceite, procesos para la preparacion de estas y su uso en formulas.
PH12017501979A1 (en) Pharmaceutical compound
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX395191B (es) Producto de avena enriquecido con avenantramidas.